close

Global IT Outage Update

Every day we care for and treat hundreds of patients from Greater Manchester and beyond who come through our doors.

 

Today's global IT outage affected many organisations including ours but to put it into context, this outage affected less than a third of our patients.

 

Our staff worked tirelessly to deliver as many chemotherapy and immunotherapy treatments as possible and continue to finalise plans for those we were unable to see today due to issues affecting our supplier.

 

Thank you for being understanding and bearing with us. Unless our teams contact you, please attend for your appointment as planned.

 

We continue to work with our supplier to resolve this issue and prioritise our most clinically urgent patients. We apologise for any delays that have occurred as a result of this.

 

Any further updates will be published on our website and social media channels (Facebook and X/Twitter)

Skip to Content

CAR-T (Chimeric Antigen Receptors Cell Therapy)

Immune cells, called T-cells, are taken from a sample of the patient’s blood. They are then reprogrammed in the lab to recognise and destroy the patient’s cancer cells. This ’living therapy’ is then given to the patient.

In 2019, The Christie joined a group of 9 NHS hospitals approved to provide Chimeric Antigen Receptors Cell Therapy (CAR-T) for adults with large B-cell lymphoma and acute lymphoblastic leukaemia for children and young people up to the age of 25.

The Christie is pleased to announce this product as a standard of care and also for clinical trials. We have been treating patients with these cells since April 2019. 

If you have any queries about our CAR-T therapy services, please email: the-christie.cart@nhs.net

Last updated: March 2023